arrow
返回
S

Steven D. Reich

john wayne cancer institute

28H指数
118论文数
3.0K被引数
收录论文 12
发表时间
MagSense® HER2, a Molecularly Targeted Magnetic Resonance Imaging Agent for the Detection of Axillary Nodal Metastasis in Subjects with Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer
err2024-05-02
err0
PREAI
errFox, Jane; Velaiutham, Shanta; Yang, Natalie; Lau, Eddie; Murugappan, Kowsi; Kumar, Beena; Laslowski, Alex; Govindarajan, Koushik; Reich, Steven; Thomas, Stephen; Neha, Nitika; Zhang, Marie; Bright, Isaac
err分享
err收藏
Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data
err2021-10-02
err27
errOAAI
errBota, Daniela A.; Mason, Warren; Kesari, Santosh; Magge, Rajiv; Winograd, Benjamin; Elias, Ileana; Reich, Steven D.; Levin, Nancy; Trikha, Mohit; Desjardins, Annick
err分享
err收藏
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors
err2017-01-09
err37
errOAAI
errShapiro, Geoffrey I.; Vaishampayan, Ulka N.; LoRusso, Patricia; Barton, Jeremy; Hua, Steven; Reich, Steven D.; Shazer, Ronald; Taylor, Carrie T.; Xuan, Dawei; Borghaei, Hossein
err分享
err收藏
Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results
err2016-09-15
err64
errOAAI
errHarrison, Simon J.; Mainwaring, Paul; Price, Timothy; Millward, Michael J.; Padrik, Peeter; Underhill, Craig R.; Cannell, Paul K.; Reich, Steven D.; Trikha, Mohit; Spencer, Andrew
err分享
err收藏
Evaluating imbalances of adverse events during biosimilar development
errMABS
IF7.3
err2016-04-06
err4
errOAAI
errVana, Alicia M.; Freyman, Amy W.; Reich, Steven D.; Yin, Donghua; Li, Ruifeng; Anderson, Scott; Jacobs, Ira A.; Zacharchuk, Charles M.; Ewesuedo, Reginald
err分享
err收藏
A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01)
err2014-11-20
err69
errOAAI
errYin, Donghua; Barker, Kerry B.; Li, Ruifeng; Meng, Xu; Reich, Steven D.; Ricart, Alejandro D.; Rudin, Dan; Taylor, Carrie T.; Zacharchuk, Charles M.; Hansson, Arne G.
err分享
err收藏
Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas
err2010-12-06
err107
PREAI
errMita, Monica M.; Spear, Matthew A.; Yee, Lorrin K.; Mita, Alain C.; Heath, Elisabeth I.; Papadopoulos, Kyriakos P.; Federico, Kristine C.; Reich, Steven D.; Romero, Ofelia; Malburg, Lisa; Pilat, MaryJo; Lloyd, G. Kenneth; Neuteboom, Saskia T. C.; Cropp, Gillian; Ashton, Edward; LoRusso, Patricia M.
err分享
err收藏
Phase 1/2 study of the vascular disrupting agent (VDA) plinabulin (NPI-2358) combined with docetaxel in patients with non-small cell lung cancer (NSCLC)
err2009-12-01
err10
PREAI
errHeist, Rebecca; Aren, Osvaldo; Millward, Michael; Mainwaring, Paul; Mita, Alain; Mita, Monica; Bazhenova, Lyudmila; Blum, Robert; Polikoff, Jonathan; Gadgeel, Shirish; Deshmukh, Chetan; Llyod, G. Kenneth; Reich, Steven; Spear, Matthew A.
err分享
err收藏
Phase I Study of Copper-Binding Agent ATN-224 in Patients with Advanced Solid Tumors
err2008-11-14
err92
PREAI
errLowndes, Sarah A.; Adams, Avril; Timms, Anthony; Fisher, Nita; Smythe, Jon; Watt, Suzanne M.; Joel, Simon; Donate, Fernando; Hayward, Carolyn; Reich, Steven; Middleton, Mark; Mazar, Andrew; Harris, Adrian L.
err分享
err收藏